Insider · CIK 0001693548
Anthony James Culverwell
Files at QNRX (Quoin Pharmaceuticals, Ltd.). First filing Dec 27, 2024, latest Sep 1, 2026.
Anthony James Culverwell files SEC Form 4 as director at QNRX (Quoin Pharmaceuticals, Ltd.). Since Dec 27, 2024, Anthony James Culverwell has reported 2 open-market buys worth $75k and 0 open-market sells worth $0, the latest filed on Sep 1, 2026.
A track record needs three past buys with six months of prices behind them; Anthony James Culverwell has 0, so none is measured yet.
The newest scored trade: bought $30k of QNRX on Aug 31, 2026, filed Sep 1, 2026, scored 38 (weak). In the last 12 months: 1 buy worth $30k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
QNRX: Quoin Pharmaceuticals, Ltd.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | Quoin Pharmaceuticals, Ltd. | $30k 6,146 shares | +18% | - | |
| 46Moderate | Quoin Pharmaceuticals, Ltd. | $45k 100,000 shares | first purchase | - |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase ADSs | +6,146 | $4.88 | $30k | 40,364 | 42 d ago |
| Aug 31, 2026 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase Ordinary Warrants (Right to Buy)derivative | +3,073 | - | - | 3,073 | 42 d ago |
| Feb 4, 2026 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +21,709 | $0.00 | $0 | 21,709 | Feb 6, 2026 |
| Aug 21, 2025 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +13,682 | $0.00 | $0 | 13,682 | Aug 25, 2025 |
| May 29, 2025 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +7,760 | $0.00 | $0 | 7,760 | Jun 3, 2025 |
| Dec 23, 2024 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase Ordinary Shares | +100,000 | $0.45 | $45k | 100,317 | Dec 27, 2024 |
| Dec 23, 2024 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase Series F Warrants (right to buy)derivative | +100,000 | - | - | 100,000 | Dec 27, 2024 |
| Dec 23, 2024 | QNRX Quoin Pharmaceuticals, Ltd. | POpen-market purchase Series G Warrants (right to buy)derivative | +100,000 | - | - | 100,000 | Dec 27, 2024 |
| Dec 9, 2024 | QNRX Quoin Pharmaceuticals, Ltd. | AGrant or award Share Option (Right to Buy)derivative | +50,714 | $0.00 | $0 | 50,714 | Dec 10, 2024 |
Questions about Anthony James Culverwell
Answered from the filings on this page, as of the latest one.
Is Anthony James Culverwell buying or selling?
In the last 12 months Anthony James Culverwell reported 1 open-market buy worth $30k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $30k of QNRX on Aug 31, 2026. Grants, option exercises and tax withholding are not counted.
How did Anthony James Culverwell's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anthony James Culverwell has 0.
Where does Anthony James Culverwell file Form 4?
Anthony James Culverwell has filed Form 4 at QNRX (Quoin Pharmaceuticals, Ltd.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.